Article
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
BMC cancer - 9 Aug 2022
Chiba Yohei, Sudo Kazuki, Kojima Yuki, Okuma Hitomi, Kohsaka Shinji, Machida Ryunosuke, Ichimura Masahiko, Anjo Kenta, Kurishita Kazumi, Okita Natsuko, Nakamura Kenichi, Kinoshita Ichiro, Takahashi Masanobu, Matsubara Junichi, Kusaba Hitoshi, Yonemori Kan, Takahashi Masamichi
Abstract excerpt
BACKGROUND: Aberrant fibroblast growth factor receptor (FGFR) signaling can substantially influence oncogenicity. Despite that FGFR gene abnormality is often detected by cancer genome profiling tests, there is no tumor-agnostic approval yet for these aberrations. E7090 (tasurgratinib) is an orally available selective tyrosine kinase inhibitor of FGFR1-3. Specific FGFR alterations were previously reported to be...
Topics
Join the communities discussing this publication.